BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Another possible acquisition would be Cold Genesys or the product they have in phase II/III trial. This product was originally owned by Biosante

Efficacy Study of Recombinant Adenovirus for Patients With Resistant Superficial Bladder Cancer (BOND)

Purpose
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of local cancer cell death and destroy tumor cells that has traveled to distant places as well as to surrounding lymph nodes.

Phase II/III trial

Interestingly the trial was updated Feb 7th, 2012 and the start date is April 2012. (Good timing)